Business
Medtronic advances its innovation strategy with intent to acquire CathWorks
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will exercise its option to acquire CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System in the U.S., Europe and Japan, where it is commercially available. The acquisition is valued at up to $585
About this update from Medtronic Plc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Deal demonstrates Medtronic's commitment to expanding pipeline through strategic investments and targeted acquisitions ","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Exercising option to acquire will bolster Medtronic's interventional cardiology portfolio, expanding its leadership in transforming how cardiovascular disease is diagnosed and treated","length":192,"tagName":"p"}]},{"val":[{"type":"text","content":"Medtronic's intent to acquire follows a 2022 strategic partnership agreement with CathWorks ","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":424,"olType":false},{"type":"text","content":"GALWAY, Ireland, Feb. 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will exercise its option to acquire CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System in the U.S., Europe and Japan, where it is commercially available. The acquisition is valued at up to $585 million with potential undisclosed earn-out payments post-acquisition.","length":616,"tagName":"p"},{"type":"text","content":""Medtronic is thrilled to move forward with our option to officially acquire CathWorks. Through our co-promotion agreement, we've seen how CathWorks can disrupt the traditional wire-based FFR segment and leverage the power of data and AI to deliver innovative solutions that assist physicians at every step of a patient's journey, from diagnosis to treatment," said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business, which is part of the Cardiovascular Portfolio at Medtronic. "This acquisition allows Medtronic to transform the cath lab with a technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care."","length":743,"tagName":"p"},{"type":"text","content":"Evaluating the physiological significance of coronary artery stenosis is essential to improving patient outcomes. Coronary physiology, most commonly assessed using fractional flow reserv...